Patent Application for Treating Disease with Dichlorphenamide

ChangeBridge: Patent Apps - Pharma (A61K)

Detected March 26th, 2026

Summary

The USPTO has published a patent application (US20260083692A1) from Strongbridge Dublin Limited for methods of treating disease using dichlorphenamide in conjunction with an organic anion transporter-1 (OAT1) substrate. The application details methods for administering the compounds and monitoring patient response and toxicity.

View original document View source feed page

What changed

This document is a published patent application from the USPTO detailing a novel method for treating diseases. The application, filed by Strongbridge Dublin Limited, describes administering dichlorphenamide alongside an organic anion transporter-1 (OAT1) substrate, with a focus on monitoring for toxicity and clinical response.

While patent applications do not impose direct regulatory obligations on companies, they signal potential future drug development and intellectual property claims in the pharmaceutical sector. Compliance officers in the pharmaceutical industry should be aware of such filings as they can indicate emerging therapeutic approaches and potential future market exclusivity for specific treatments.

Source document (simplified)

← USPTO Patent Applications

METHODS OF TREATING DISEASE WITH DICHLORPHENAMIDE

Application US20260083692A1 Kind: A1 Mar 26, 2026

Assignee

Strongbridge Dublin Limited

Inventors

Fredric Jay COHEN

Abstract

Provided herein are methods for administering dichlorphenamide, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the subject is also being administered an organic anion transporter-1 (OAT1) substrate to treat an associated disease or disorder. The method comprises administering to the subject a therapeutically effective amount of dichlorphenamide, or a pharmaceutically acceptable salt thereof, and monitoring the subject for signs and symptoms of toxicity and clinical response associated with the OAT1 substrate.